Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Will Novavax Hit $250 This Year?

TheMotleyFool

0 0

Will Novavax Hit $250 This Year?Photo, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

Vaccine maker Novavax (NASDAQ: NVAX) has fallen harder than the broader market of late, dropping by 36% in the past three months alone. Investors' views of the biotech have fluctuated along with news surrounding the pandemic, as well as what some of its competitors in the COVID-19 vaccine market are up to.

But despite Novavax's recent issues, Wall Street has high hopes for the stock. The company's average one-year price target currently stands at a whopping $250, according to Yahoo! Finance. Meanwhile, Novavax's shares are trading at $95.22. Can the company hit this mark within the next 12 months?